The role of intensive chemotherapy in myelodysplastic syndromes.

We review results of intensive chemotherapy (IC) obtained in myelodysplastic syndromes (MDS). Overall, the complete remission (CR) rates and median CR duration obtained with IC are low in MDS, especially when compared to results obtained in de novo AML treated with the same chemotherapy regimens; very few MDS patients achieve prolonged remissions. Failure to achieve CR, in MDS, results both from a high incidence of resistant disease and toxic deaths, the latter being due to longer periods of aplasia than in de novo AML. However some subgroups of MDS seem to obtain higher CR rates and more prolonged remissions. These include patients younger than 45 to 50 years, those with a large excess of marrow blasts or Auer rods at diagnosis, and patients with a normal karyotype or at least without involvement of chromosomes 5 and/or 7. Results of IC clearly have to be improved in MDS. Higher CR rates may possibly be obtained by intensifying induction regimens, but this will probably require the addition of growth factors, in order to reduce the already very long periods of aplasia seen with IC in MDS. For consolidation therapy, new approaches, and especially autologous bone marrow transplantation, will have to be investigated.

[1]  D. Oscier,et al.  Clonality of cell populations in refractory anaemia using combined approach of gene loss and X‐linked restriction fragment length polymorphism‐methylation analyses , 1991, British journal of haematology.

[2]  P. Morel,et al.  Prognostic factors in adult de novo myelodysplastic syndromes treated by intensive chemotherapy , 1991, British journal of haematology.

[3]  C. Lorthois,et al.  Therapy related myelodysplastic syndrome and leukemia with no "unfavourable" cytogenetic findings have a good response to intensive chemotherapy: a report on 15 cases. , 1991, Leukemia & lymphoma.

[4]  H. Dohy,et al.  Effect of granulocyte colony-stimulating factor after intensive induction therapy in relapsed or refractory acute leukemia. , 1990, The New England journal of medicine.

[5]  S. Larsen,et al.  Chromosome aberrations and prognostic factors in therapy-related myelodysplasia and acute nonlymphocytic leukemia. , 1990, Blood.

[6]  C. Haanen,et al.  Intensive antileukemic treatment of patients younger than 65 years with myelodysplastic syndromes and secondary acute myelogenous leukemia , 1990, Cancer.

[7]  S. Thibodeau,et al.  Clonal studies in the myelodysplastic syndrome using X-linked restriction fragment length polymorphisms. , 1990, Blood.

[8]  R. Storb,et al.  Bone marrow transplantation for patients with myelodysplasia. Pretreatment variables and outcome. , 1990 .

[9]  L. Robison,et al.  Refractory anemia with excess of blasts in transformation hematologic and clinical study of 52 patients , 1989, Cancer.

[10]  S. Nimer,et al.  Efficacy of intensive chemotherapy for acute myelogenous leukemia associated with a preleukemic syndrome. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  A. Audebert,et al.  Refractory anemia with excess of blasts in transformation. Clinical, hematologic, and cytogenetic findings in nine patients. , 1989, Cancer genetics and cytogenetics.

[12]  O. Taboureau,et al.  Cytogenetics and their prognostic value in childhood and adult acute lymphoblastic leukemia (ALL) excluding L3 , 1989, Hematological oncology.

[13]  P. Greenberg,et al.  Treatment of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor. A phase I-II trial. , 1989, Annals of internal medicine.

[14]  P. Fenaux,et al.  Favorable cytogenetic abnormalities in secondary leukemia , 1989, Cancer.

[15]  R. Gray,et al.  AML associated with previous cytotoxic therapy, MDS or myeloproliferative disorders: results from the MRC's 9th AML trial , 1989, British journal of haematology.

[16]  K. Miyazono,et al.  Treatment of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor: a preliminary report. , 1989, The American journal of medicine.

[17]  P. Martiat,et al.  Intensive chemotherapy for acute non‐lymphoblastic leukemia after primary myelodysplastic syndrome , 1988, Hematological oncology.

[18]  P. Mazza,et al.  Treatment‐related leukemia in Hodgkin's disease: A multi‐institution study on 75 cases , 1987, Hematological oncology.

[19]  H. Kantarjian,et al.  Therapy-related leukemia and myelodysplastic syndrome: clinical, cytogenetic, and prognostic features. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  R. Simon,et al.  A critical appraisal of low-dose cytosine arabinoside in patients with acute non-lymphocytic leukemia and myelodysplastic syndromes. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  Levin Eg,et al.  Secondary myelodysplastic syndromes and leukaemias. , 1986 .

[22]  R. Larson,et al.  High‐dose cytosine arabinoside in the treatment of preleukemic disorders: A leukemia intergroup study , 1986, American journal of hematology.

[23]  H. Kantarjian,et al.  The association of specific “favorable” cytogenetic abnormalities with secondary leukemia , 1986, Cancer.

[24]  B. Vogelstein,et al.  Differentiation of leukemia cells to polymorphonuclear leukocytes in patients with acute nonlymphocytic leukemia. , 1986, The New England journal of medicine.

[25]  G. Tricot,et al.  The role of aggressive chemotherapy in the treatment of the myelodysplastic syndromes , 1986, British journal of haematology.

[26]  D. Arthur,et al.  Therapy-related acute myeloid leukemia and myelodysplastic syndrome: a clinical and morphologic study of 65 cases. , 1985, Blood.

[27]  A. Zander,et al.  Treatment of patients over 50 years of age with acute myelogenous leukemia with a combination of rubidazone and cytosine arabinoside, vincristine, and prednisone (ROAP) , 1981 .

[28]  H. Thaler,et al.  Morphological Classification, Response to Therapy, and Survival in 263 Adult Patients With Acute Nonlymphoblastic Leukemia , 1980 .